Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 76

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 76
---
 or in greater scope than, Yissum’s obligations or liabilities under the license agreement; or (b) require the sublicensee to enter into a new license agreement on substantially the same terms and conditions as those contained in the license agreement.

We have the first right to prepare, file, prosecute and maintain any patent applications and patents in respect of the licensed technology and any part thereof, at our expense, subject to certain conditions. We are required to file each licensed patent application at least in the United States, Europe and Japan. We are also required to take action, in reasonable commercial circumstances and after consultation with patent counsel, in the prosecution, prevention or termination of any infringement of patents licensed under the agreement. We are responsible for the expenses of any patent infringement suit that we bring, including the expenses incurred by Yissum in connection with such suits. We are entitled to reimbursement from any awards or settlements recovered in such suit or in the settlement thereof for all costs and expenses involved in the prosecution of any such suit. If we elect not to pursue any action in connection with infringement and Yissum in good faith disagrees with us that it is in the mutual best interest of both parties not to pursue any such action, then, at our election, we may either allow Yissum to pursue such actions, at Yissum’s expense, or pay Yissum the royalties that Yissum would otherwise receive from us attributable to lost sales resulting from such alleged infringement

Upon completion and presentation to us by Yissum of the research development program, on October 25, 2023, LipoVation and Yissum entered into an amendment to the initial Yissum License Agreement, reducing the sublicense fees from 15% to 13% and providing that Yissum will not pursue with any third party any research, development or commercialization efforts with respect to uses or indications of the Licensed Technology within the Field of which they become aware but which are not part of a Research Program. In addition, as of October 25, 2023, LipoVation and Yissum agreed on an approved initial budget for research and development efforts.

<div align='center'>46</div>

Pursuant to the Yissum Agreements, if Yissum achieves the following milestones, LipoVation will be obligated to make the following milestone payments:

| Milestone                                                                              |     | Payment |         |
|:---------------------------------------------------------------------------------------|:----|:--------|--------:|
| Upon First patient enrolled in a Phase I